ORY-4001 / Oryzon - LARVOL DELTA

Earlier stage programs (Oryzon Press Release) - "ORY-4001, Oryzon’s highly selective histone deacetylase 6 (HDAC6) inhibitor nominated as a clinical candidate for the treatment of certain neurological diseases such as Charcot-Marie-Tooth disease (CMT), Amyotrophic Lateral Sclerosis (ALS) and others, continues to progress through IND enabling studies to prepare it for clinical studies."

Clinical • Amyotrophic Lateral Sclerosis • Genetic Disorders